17466-00-1

Upstream product

• 62-53-3 aniline 
• 41259-65-8 6-chloro-N₄-phenylpyrimidine-4,5-diamine 

Downstream Products

• 23000-53-5 7-piperidino-3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine 
• 74414-60-1 7-Methoxy-3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine 
• 5719-08-4 4-chloro-1H-pyrimido[4,5-b]indole 
• 74414-61-2 7-ethoxy-3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine 
• 74414-68-9 4-hydroxy-4-methyl-1-(3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidin-7-yl)-2-pentanone 
• 74529-02-5 3-Phenyl-7-(toluene-4-sulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 74414-82-7 3-Phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine-7-carbonitrile 
• 74136-42-8 7-phenyl-3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine 
• 68011-99-4 N-(3-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-hydroxylamine 
• 69591-19-1 (6-chloropyrimidin-4-yl)phenylamine 
• 13925-57-0 7-amino-3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine 
• 20271-39-0 5-amino-1-phenyl-1H-1,2,3-triazole-4-carbonitrile 
• 139300-70-2 7-iodo-3-phenyl-3H-1,2,3-triazolo<4,5-d>pyrimidine 
• 74414-54-3 (3-Phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-hydrazine 

Relevant academic research and scientific papers

GLUCOSE TRANSPORT INHIBITORS

The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation

The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidases-related diseases and disorders and inhibition of platelet activation.